Serum amyloid P component induces neuronal apoptosis and β-amyloid immunoreactivity

Brain Research

Volumn 988, Issue 1-2, 2003, Pages 69-77

  Urbányi, Zoltán ^a   László, Lajos ^b   Tomasi, Thomas B ^c   Tóth, Erzsébet ^a   Mekes, Éva ^a   Sass, Miklós ^b   Pázmány, Tamás ^a,c  

^a GEDEON RICHTER LTD   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Amyloid P; Apoptosis; Neurodegeneration; Nuclear localization; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID P COMPONENT; PROTEIN BAX; PROTEIN BCL 2;

ALZHEIMER DISEASE; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CELL STRUCTURE; CELL TYPE; CONTROLLED STUDY; DEGENERATIVE DISEASE; IMMUNOELECTRON MICROSCOPY; IMMUNOREACTIVITY; INTRACELLULAR TRANSPORT; MICROSCOPY; MOLECULAR MECHANICS; NERVE CELL; NERVE CELL MEMBRANE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; TARGET CELL;

EID: 0142011170     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03345-6     Document Type: Article

References (39)

1. Botto M., Hawkins P.N., Bickerstaff M.C.M., Herbert J., Bygrave A.E., McBride A., Hutchinson W.L., Tennent G.A., Walport M.J., Pepys M.B. Amyloid deposition is delayed in mice with targeted deletion of serum amyloid P component gene. Nature Med. 3:1997;855-859.
2. Du Clos T.W., Mold C., Stump R.F. Identification of a polypeptide sequence that mediates nuclear localization of the acute phase protein C-reactive protein. J. Immunol. 145:1990;3869-3875.
3. Duong T., Acton P.J., Johnson R.A. The in vitro neuronal toxicity of pentraxins associated with Alzheimer's disease brain lesions. Brain Res. 813:1998;303-312.
4. Emsley J., White H.E., O'Hara B.P., Oliva G., Srinivasan N., Tickle I.J., Blundell T.L., Pepys M.B., Wood S.P. Structure of pentameric human serum amyloid P component. Nature. 367:1994;338-345.
5. Erdö S.L., Michler A., Wolff J.R., Tytko H. Lack of excitotoxic cell death in serum-free cultures of rat cerebral cortex. Brain Res. 526:1990;328-332.
6. Glenner G., Wong Alzheimer's disease C.W. Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885-890.
7. 2+-dependent binding of human serum amyloid P component to Alzheimer's β-amyloid peptide. J. Biol. Chem. 270:1995;10392-10394.
8. Hamazaki H. Amyloid P component promotes aggregation of Alzheimer's β-amyloid peptide. Biochem. Biophys. Res. Commun. 211:1995;349-353.
9. Hasegawa M., Kawashima S., Shikano M., Kojima K., Yanai T., Hassegawa H., Tomita M., Murakami K., Kawamura N., Katsumata H. C1q complexes with β-2-microglobulin and amyloid P-component in sera of patients with dialysis-associated amyloidosis. Nephron. 69:1995;380-383.
10. Hashimoto S., Katou M., Dong Y., Murakami K., Terada S., Inoue M. Effects of hormone replacement therapy on serum amyloid P component in postmenopausal women. Maturitas. 26:1997;113-119.
11. Hawkins P.N., Wootton R., Pepys M.B. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J. Clin. Invest. 86:1990;1862-1869.
12. Hawkins P.N., Rossor M.N., Gallimore J.R., Miller B., Moore E.G., Pepys M.B. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem. Biophys. Res. Commun. 201:1994;722-726.
13. Inoue S., Kuroiwa M., Kisilevsky R. Basement membranes, microfibrils and β amyloid fibrillogenesis in Alzheimer's disease: high resolution ultrastructural findings. Brain Res. Rev. 29:1999;218-231.
14. Iversen L.L., Mortishire-Smith R.J., Pollack S.J., Shearman M.S. The toxicity in vitro of β-amyloid protein. Biochem. J. 311:1995;1-16.
15. Jager L., Hazenberg B.P.C., Franssen E.J.F., Limburg P.C., van Rijswijk M.H., Piers D.A. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J. Nucl. Med. 39:1998;699-706.
16. Jiang H., Burdick D., Glabe C.G., Cotman C.W., Tenner A. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:1994;5050-5059.
17. Kalaria R.N. Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease. Res. Immunol. 143:1992;637-641.
18. Kalaria R.N., Grahovac I. Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease. Brain Res. 516:1990;349-353.
19. Kalaria R.N., Galloway P.G., Perry G. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol. Appl. Neurobiol. 17:1991;189-201.
20. Kalaria R.N., Golde T.E., Cohen M.L., Younkin S.G. Serum amyloid P in Alzheimer's disease. Implications for dysfunction of the blood-brain barrier. Ann. NY Acad. Sci. 640:1991;145-148.
21. László L., Tuckwell J., Self T., Lowe J., Landon M., Smith S., Hawthorne J.N., Mayer R.J. The latent membrane protein-1 in Epstein-Barr virus-transformed lymphoblastoid cells is found with ubiquitin-protein conjugates and heat-shock protein 70 in lysosomes oriented around the microtubule organising centre. J. Pathol. 164:1991;203-214.
22. LeBlanc A. Increased production of 4 kDa Amyloid β peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J. Neurosci. 15:1995;7837-7846.
23. Mattson M.P. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77:1997;1081-1132.
24. McGeer E.G., Yasojima K., Schwab C., McGeer P.L. The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol. Aging. 22:2001;843-848.
25. Müller-Hill B., Beyreuther K. Molecular biology of Alzheimer's disease. Annu. Rev. Biochem. 58:1989;287-307.
26. Nybo M., Olsen H., Jeune B., Andersen-Ranberg K., Nielsen E.H., Svehag S.-E. Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dement. Geriatr. Cogn. Disord. 9:1998;126-129.
27. Pepys M.B., Booth D.R., Hutchinson W.L., Gallimore J.R., Collins P.M., Hohenester E. Amyloid P component. A critical review. Amyloid: Int. J. Exp. Clin. Invest. 4:1997;274-295.
28. Pepys M.B. C-reactive protein and amyloidosis: from proteins to drugs. Williams G. Horizons in Medicine. vol. 10:1999;397-414 Royal College of Physicians, London.
29. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., Lovat L.B., Bartfai T., Alanine A., Hertel C., Hoffmann T., Jakob-Roetne R., Norcross R.D., Kemp J.A., Yamamura K., Suzuki M., Taylor G.W., Murray S., Thompson D., Purvis A., Kolstoe S., Wood S.P., Hawkins P.N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417:2002;254-259.
30. Perlman H., Zhang X., Chen M.W., Walsh K., Buttyan R. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ. 6:1999;48-54.
31. Perlmutter L.S., Barrón E., Myers M., Saperia D., Chui H.C. Localization of amyloid P component in human brain: Vascular staining patterns and association with Alzheimer's disease lesions. J. Comp. Neurol. 352:1995;92-105.
32. Perry V.H., Anthony D.C., Bolton S.J., Brown H.C. The blood-brain barrier and the inflammatory response. Mol. Med. Today. 3:1997;335-341.
33. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, New York. 9.16.
34. Schägger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrilamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:1987;368-379.
35. Skinner M., Cohen A.S. Amyloid P component. Di Sabato G. Methods in Enzymology. vol. 163:1988;523-536 Academic Press, San Diego.
36. Tennent G.A., Lovat L.B., Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. USA. 92:1995;4299-4303.
37. Urbányi Z., Lakics V., Erdö S.L. Serum amyloid P component-induced cell death in primary cultures of rat cerebral cortex. Eur. J. Pharmacol. 270:1994;375-378.
38. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.
39. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 887:2000;80-89.